Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
|Articles|March 3, 2010
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-03-2010
- Volume 6
- Issue 3
Pfizer Outlines Postacquisition Manufacturing Strategy
Author(s)Pharmaceutical Technology Editors
Following its $68-billion acquisition of Wyeth, Pfizer is integrating its manufacturing and outsourcing activities (Podcast).
Advertisement
Following its $68-billion acquisition of Wyeth (Madison, NJ), Pfizer (New York) is integrating its manufacturing and outsourcing activities. In a joint
Articles in this issue
over 16 years ago
The Opportunities, Challenges, and Trends in Biomanufacturingover 16 years ago
A Bio View of Outsourcingover 16 years ago
Roundup of Informex 2010Advertisement
Related to this article
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5